Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients
Abstract Recurrent respiratory papillomatosis (RRP) is a human papilloma virus (HPV)‐driven benign neoplasm, affecting larynx, trachea, and even lung, leading to voice disorders, airway obstruction, and postobstructive pneumonia. Several case reports have documented the promising efficacy of intrave...
Main Authors: | Zengjun Liu, Yang Xiao, Jing Xu, Mengyao Liu, Mingyong Han, Wenyu Hu, Dongyuan Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-04-01
|
Series: | Laryngoscope Investigative Otolaryngology |
Subjects: | |
Online Access: | https://doi.org/10.1002/lio2.1013 |
Similar Items
-
Successful bevacizumab therapy in a 25-year-old patient with recurrent respiratory papillomatosis
by: Gita Dambrova, et al.
Published: (2024-09-01) -
Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022
by: Laura Torres-Canchala, et al.
Published: (2022-12-01) -
Systemic bevacizumab for recurrent respiratory papillomatosis. A case series
by: Kristine Grubbe Gregersen, et al.
Published: (2023-12-01) -
Recurrent respiratory papillomatosis: A 2020 perspective
by: Jacob J. Benedict, et al.
Published: (2021-04-01) -
A case report describing the use of systemic bevacizumab in the treatment of recurrent respiratory papillomatosis with pulmonary involvement
by: Amy O'Brien, et al.
Published: (2023-12-01)